title: In vitro induction of specific CD8+ T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma.
abstract: The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined for in vitro induction of peptide-specific CD8(+) T lymphocyte (CD8(+)TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8(+)TL and in vivo immune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8(+)TL for at least one peptide were detectable in 21/35 patients (60.0%). The potent peptides were SART-1(690) in 9/35 (25.7%), SART-2(93), and ART4(75) in 7/35 (20.0%), respectively. In the 9 patients with SART-1(690)-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1(690)-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3(+) T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1(690), SART-2(93), and ART4(75) could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.
authors.affiliation: Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Higashi-ku, Fukuoka, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Toyoshima
authors.forename: Wataru
authors.initials: W
authors.lastname: Kumamaru
authors.forename: Jun-nosuke
authors.initials: JN
authors.lastname: Hayashida
authors.forename: Masahumi
authors.initials: M
authors.lastname: Moriyama
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kitamura
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Akira
authors.initials: A
authors.lastname: Yamada
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Seiji
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D036002:ADP Ribose Transferases / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D004268:DNA-Binding Proteins / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000096:biosynthesis; D008565:Membrane Proteins / Q000276:immunology; D009062:Mouth Neoplasms / Q000276:immunology*; D009363:Neoplasm Proteins / Q000276:immunology; D017411:Ribonucleoproteins, Small Nuclear / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D017411:Ribonucleoproteins, Small Nuclear; C431323:SART1 protein, human; D007371:Interferon-gamma; D036002:ADP Ribose Transferases; C105234:ART4 protein, human; C405383:DSE protein, human